Quality assurance in total body irradiation by Rittmann, K.L.
Rittmann: Quality assurance in total body irradiation
QUALITY ASSURANCE IN TOTAL BODY IRRADIATION
K. L. RITTMANN
Abteilung Strahlentherapie und spezielle Onkologie, Medizinische Hochschule Hannover
D 30623 Hannover, Germany
The central aspect of all quality
assurance programs in radiotherapy is to
guarantee the prescribed dose and dose
distribution in every treated patient. This should
assure as much as possible benefit from the
intended treatment and should also facilitate the
comparison of treatment results of multicentrical
studies. In general radiotherapy is an
interdisciplinary task and especially this is true
for total body irradiation (TBI) prior to bone
marrow transplantation (BMT). Many factors
influence the clinical outcome of this combined
treatment modality and their interaction is by far
not well understood, although till now several
thousands TBI/BMT have been performed
world-wide. The International Bone Marrow
Transplant Registries (IBMTR) and the
European group for Blood and Marrow
Transplantation (EBMT) collected the
parameters and the results of treatments for
evaluation. However there are serious
difficulties concerning the evaluation of gathered
clinical data so far because of differences in
procedures used for both medical and physical
approach [Sanchez-Doblado et al. 1995]. It is
nearly self-evident, that a quality management
[e.g. ISO 9004-2:1991] covering the whole
complex treatment would be useful.
Quality assurance in TBI starts with the
clinical diagnosis and with the formulation of the .
therapeutical concept. The requirements on
diagnostic imaging modalities, surgical and
pathological procedures etc. will be omitted in
this context. A clear dose prescription is a
prerequisite for all following steps in TBI [e.g.
AAPM 1986, QUAST 1988, Sanchez-Doblado et
al. 1995]. This is not self-evident and contrasts
with more conventional radiation therapy
treatment situations, where often a single
number for prescription and description of dose
is sufficient [ICRU 1993]. The reason lies in the
complex target volume in TBI and additionally in
the variety of treatment techniques applied. As
an absolute minimum we need at least one point
to which the prescribed dose can be referred.
Now most centres use the midpoint of abdomen
at the level of the umbilicus for prescription. It is
clearly evident that this alone is unsufficient for a
halfway informative description of dose and
dose distribution in the patient.
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Therapeutic TBI doses, alone or in
combination with chemotherapy, may exceed
the tolerance of certain organs, for instance
lungs, eye lens, etc. In particular, the lungs are
the most critical organ at risk, because
interstitial pneumonitis is one of the main
causes for fatal treatment complications in TBI
[e.g. Barrett et al. 1983, Keane et al. 1981,
Morgan et al. 1996, Trott 1992, Weiner et al.
1986]. The radiotherapist should therefore
specify the dose the lung should receive and
often this makes additional lung shielding
necessary. The fractionation scheme and the
dose rate because of its special importance for
the development of pneumonitis in single-dose
TBI should clearly be stated.
Clinical treatment planning for TBI
differs in some distinctive points from
conventional radiotherapy procedures. The
localization/simulation consists mainly in taking
radiographs of the thorax in order to delineate
the lung areas to be shielded. Ideally this should
be done under treatmenf conditions. Normal
therapy simulators do not suit well for this task
because of their restricted geometry. Some
centres use therefore diagnostic x-ray units or
even the treatment machine. Radiotherapists
should take care to delineate the area to be
shielded not too large. This could result in
underdosage of not assigned parts of the target
volume, for instance the lymph nodes below the
clavicles. For the evaluation of clinical data the
shielded volume of the lungs should be
estimated.
Physical treatment planning mostly rests
on calculation schemes that have been
developed and adjusted to the special treatment
situations in the departments. Otten it is
supported by self-made computer programs.
Even modern commercially available therapy
planning systems do not enable the medical
physicist to calculate dose distributions in TBI
for daily routine and further development seems
urgently necessary.
Basic phantom dosimetry and patient
dosimetry for compensation of contour variation
and for inhomogeneity correction especially for
lung dose determination should be performed
under TBI conditions [e.g. AAPM 1986, Quastet
al. 1990, Sanchez-Doblado et aI.1995]. A
careful dosimetry under TBI conditions
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simulating closely the patient's treatment
situation is also strongly recommended because
of the before mentioned limitations of the
calculation methods.
Treatment verification in TBI is similiar
to that in conventional radiotherapy. It consists
in controlling the different treatment parameters
like patient position, alignment of shielding
blocks and compensators or boli and correct
machine settings. The recommended or
prescribed protocols for quality assurance of
radiotherapy machines apply also to this
distinctive treatment modality. Port filming is the
method of choice to control especially the
correct position of shielding blocks of the lungs.
In vivo dosimetry has a distinctive
importance for quality assurance in TBI, despite
all the technical and systematical limitations
associated with this method [Rittmann 1996].
This contrasts clearly with conventional
radiotherapy, where it plays only a minor role.
An important reason for the use of in vivo
dosimetry is, that in TBI a high dose is delivered
in a relative short time. Therefore it is usually not
possible to correct faulty procedures [Christ et
a!. 1991]. Additionally in vivo dosimetry yields
valuable information. about dose and dose
distribution in this complex target volume
considering in particular the inherent problems
with the calculation schemes. Subsequently it is
possible to minimize the dose deviations from
the prescribed values, what hopefully helps
each individual patient.
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